What to Ask Your Doctor If You’re Entering the Menopause Transition

Perimenopause—the years leading up to the final menstrual period—is a natural biological transition that can bring a wide range of symptoms: irregular periods, hot flashes, sleep disruption, mood changes, cognitive fog, and more. For many people, these changes are mild; for others, they significantly affect quality of life. Understanding what is happening physiologically, what current evidence says about management options, and what questions to raise with your clinician can help you navigate this transition with clarity and confidence.

What the Menopause Transition Is in Plain Language

Menopause is defined as one year after the final menstrual period. The transition leading up to that point—called perimenopause—can last anywhere from a few months to more than a decade, during which hormone levels fluctuate and menstrual cycles become irregular. The average age of natural menopause in the United States is around 51 years, but the perimenopausal transition typically begins in the mid-to-late 40s for most people.

During perimenopause, the ovaries produce progressively less estrogen and progesterone, leading to the hormonal changes that drive symptoms. The experience is highly variable: some people navigate perimenopause with minimal disruption, while others experience symptoms that substantially affect work, relationships, and overall well-being.

ACOG’s patient education materials^[1] describe the perimenopausal years as a period of physiologic change, and note that symptoms may begin before the final period.

After the final menstrual period, the postmenopausal phase begins—a permanent state that carries its own health considerations, including changes in bone density and cardiovascular risk that are partially mediated by lower estrogen levels.

Why It Matters: What Guidelines Say

The North American Menopause Society (NAMS) is the leading professional body focused on menopause management in North America. Its 2022 Hormone Therapy Position Statement^[2] is one of the most comprehensive and widely referenced evidence reviews on this topic.

Key highlights from the NAMS 2022 statement^[3] include:

• Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (hot flashes and night sweats) and the genitourinary syndrome of menopause.
• HT has been shown to prevent bone loss and fracture.
• The risks of HT differ depending on type, dose, duration, route of administration, timing of initiation, and whether a progestogen is used.
• For women under 60 or within 10 years of menopause onset without contraindications, the benefit-risk ratio is described as favorable for treatment of bothersome symptoms and prevention of bone loss.
• Treatment should be individualized using the best available evidence, with shared decision-making and periodic re-evaluation.

ACOG similarly supports individualized, shared decision-making regarding hormone therapy.

This information is presented here as general education. Whether hormone therapy is appropriate, beneficial, or safe for any individual person is a clinical question that depends on that person’s full medical history, current health status, preferences, and values. No one should start, stop, or modify hormone therapy based on general educational content—these decisions belong in a conversation with a qualified clinician.

The Menopause Society (NAMS) also addresses perimenopause specifically^[4], noting that weight management, brain fog awareness, and sleep disruption are common concerns during the transition.

Common Symptoms and Drivers at the Population Level

Symptoms of the menopause transition are primarily driven by declining and fluctuating estrogen levels, though other hormonal and non-hormonal factors play a role.

Vasomotor symptoms (hot flashes and night sweats): The most commonly reported symptoms, estimated to affect approximately 75% of people going through menopause. Hot flashes involve a sudden sensation of warmth, often in the face and chest, sometimes accompanied by sweating and chills. Night sweats are hot flashes occurring during sleep and are a major driver of sleep disruption.

Menstrual changes: Cycles become longer, shorter, heavier, or lighter in the years before the final period. Cycles may also become unpredictable. Clinicians distinguish expected perimenopausal changes from abnormal uterine bleeding that warrants investigation.

Sleep disturbances: Often linked to night sweats but can occur independently of vasomotor symptoms.

Genitourinary syndrome of menopause (GSM): Lower estrogen levels cause thinning and reduced lubrication of vaginal tissue, which can lead to dryness, discomfort, and changes in urinary function. Unlike vasomotor symptoms, GSM tends to be progressive without treatment.

Mood changes: Increased risk of low mood, anxiety, and irritability is recognized during the perimenopausal transition. Women with a prior history of depression or mood sensitivity to hormonal changes (such as premenstrual dysphoric disorder) may be particularly affected.

Cognitive symptoms (“brain fog”): Mild difficulties with memory and concentration are common during perimenopause. NAMS notes^[4] that changes in cognitive performance are typically mild and within normal limits, and dementia at midlife is very rare.

Changes in bone density: Estrogen plays a protective role in bone metabolism. The perimenopausal years are associated with accelerating bone density loss, which becomes more pronounced after the final period.

Cardiovascular changes: Estrogen has cardioprotective effects, and post-menopause cardiovascular risk rises—though this is also driven by aging and lifestyle factors.

What Follow-Up Evaluation May Be Considered

This section is general education. Evaluation decisions depend on your individual clinical picture.

A clinician evaluating a person in the menopause transition may consider:

Clinical history and symptom review: Understanding which symptoms are present, their severity, and how much they affect daily functioning. Validated tools exist to help document symptom burden.

Hormone testing: Follicular stimulating hormone (FSH) and estradiol levels are not typically needed to diagnose perimenopause in women over 45 years of age—the diagnosis is primarily clinical. However, hormone testing may be considered for younger women or in ambiguous situations.

Thyroid function: Thyroid disorders are common in midlife women and can produce symptoms that overlap with perimenopausal symptoms—fatigue, mood changes, menstrual irregularity. A thyroid test is often a reasonable part of the workup.

Bone density (DEXA scan): ACOG and other guidelines recommend bone density testing at menopause for women at elevated osteoporosis risk; baseline DEXA is often discussed in this transition period.

Cardiovascular risk assessment: The menopause transition is an appropriate time to discuss heart health, including blood pressure, cholesterol, and metabolic markers.

Endometrial evaluation: Abnormal uterine bleeding—particularly bleeding between periods, after intercourse, or post-menopause—warrants evaluation to rule out concerning causes.

Lifestyle and Prevention Factors the Evidence Supports

NAMS^[4] notes that weight gain around the menopause transition can be prevented by diet and exercise, and that weight loss of as little as 3–5% can provide health improvements including better cholesterol levels and reduced diabetes risk.

Evidence-supported approaches include:

• Regular aerobic and resistance exercise: Benefits include reduced vasomotor symptom frequency for some people, better sleep, mood support, weight management, and bone density preservation.
• Dietary patterns: A diet rich in vegetables, fruits, whole grains, and lean protein, with limited refined carbohydrates and saturated fat, supports metabolic health during this transition.
• Smoking cessation: Smokers tend to reach menopause earlier and experience more severe vasomotor symptoms.
• Alcohol moderation: Alcohol can trigger hot flashes in some people and affects sleep quality and bone health.
• Maintaining a healthy weight: Adipose tissue produces estrogens, which affects the hormonal picture in complex ways; weight management remains broadly beneficial for metabolic and cardiovascular health.
• Stress management and sleep hygiene: Sleep disruption is one of the most burdensome perimenopausal symptoms; behavioral approaches to sleep—including consistent schedules, cool sleeping environments, and stress reduction—have evidence support.
• Calcium and vitamin D: Important for bone health; discuss appropriate intake and supplementation needs with your clinician.

Questions to Bring to Your Appointment

Choose the questions most relevant to your experience:

• Are my symptoms consistent with what you would expect from the menopause transition, or could other causes be contributing?
• How do we know when I have reached perimenopause, and do I need hormone testing?
• Should my thyroid function be checked given these symptoms?
• What options are generally available for managing hot flashes and night sweats—hormonal and non-hormonal?
• Can you walk me through the NAMS 2022 hormone therapy position statement in terms of what it might mean for my situation?
• What would make me a good or poor candidate for hormone therapy from a risk-benefit standpoint?
• How does the route of administration (oral, transdermal, etc.) and type of hormone affect risks?
• What options exist for genitourinary symptoms like vaginal dryness, and can those be treated separately from vasomotor symptoms?
• Should I have a bone density test now, and if so, how will results guide my care?
• Is this an appropriate time to review my cardiovascular risk factors comprehensively?
• How do exercise and diet specifically affect menopause symptoms and long-term health during this transition?
• What monitoring would be recommended if I start any treatment, and how often should we reassess?

Red Flags Warranting Prompter Follow-Up

While perimenopausal symptoms are expected, certain patterns warrant more timely clinical evaluation:

• Postmenopausal bleeding—any vaginal bleeding one year or more after the final period—requires evaluation promptly, as it has several possible causes that need to be assessed
• Unusually heavy perimenopausal bleeding (soaking a pad or tampon every hour or more) warrants prompt evaluation
• New or worsening pelvic pain
• Symptoms of severe depression, including thoughts of self-harm (if you are in crisis, contact 988, the Suicide and Crisis Lifeline, or your local emergency services)
• Symptoms that could suggest other causes—severe fatigue, significant unintended weight change, or prominent cardiac symptoms—warrant evaluation to rule out other conditions

Key Takeaways

• Perimenopause is a natural transition that can last years and produces a wide range of symptoms driven by fluctuating estrogen levels.
• The NAMS 2022 Hormone Therapy Position Statement describes hormone therapy as the most effective treatment for vasomotor symptoms, with favorable benefit-risk balance for most healthy women under 60 or within 10 years of menopause onset—but individual suitability requires a personalized clinical discussion.
• Symptoms include hot flashes, night sweats, sleep disruption, mood changes, genitourinary changes, and mild cognitive symptoms.
• Lifestyle factors—exercise, diet, weight management, and behavioral sleep strategies—have meaningful roles in symptom management and long-term health.
• This is an important time to discuss bone density, cardiovascular risk, and thyroid health with your clinician.
• Postmenopausal bleeding (after 12 months without a period) always warrants prompt clinical evaluation.

Disclaimer: This content is for general educational purposes only and is not medical advice. It does not create a doctor-patient relationship. Always talk to your licensed healthcare professional about your specific situation.

Post Views: 4